U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H11FN2OS
Molecular Weight 273.316
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FLUTEMETAMOL F-18

SMILES

CNC1=C([18F])C=C(C=C1)C2=NC3=C(S2)C=C(O)C=C3

InChI

InChIKey=VVECGOCJFKTUAX-HUYCHCPVSA-N
InChI=1S/C14H11FN2OS/c1-16-11-4-2-8(6-10(11)15)14-17-12-5-3-9(18)7-13(12)19-14/h2-7,16,18H,1H3/i15-1

HIDE SMILES / InChI
Molecular Formula C14H11FN2OS
Molecular Weight 273.316
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Flutemetamol F 18 is a radioactive molecular agent that is intended for use with PET imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia. Flutemetamol F 18 consists of flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 and it selectively binds to cerebral fibrillar beta-amyloid, a peptide involved in Alzheimer's disease.

CNS Activity

CNS Penetrant
2588
Curator's Comment: Following intravenous injection, flutemetamol F 18 diffuses across the human blood-brain barrier and produces a radioactivity signal detectable throughout the brain. Subsequently, cerebral perfusion decreases the brain flutemetamol F 18 content, with differential retention of the drug in cortical areas that contain β-amyloid aggregates compared to areas that lack the aggregates. The time-activity curves for flutemetamol F 18 in the brain of subjects with positive scans shows continual signal increases from time zero through 30 minutes post administration, with stable values thereafter up to at least 120 minutes post-injection.

Originator

Approval Year

2013
589
Targets

Targets

Primary TargetPharmacologyConditionPotency
Amyloid beta A4 protein
4
Target ID: P05067|||Q13764|||Q8WZ99
Gene ID: 351.0
Gene Symbol: APP
Target Organism: Homo sapiens (Human)
Binding Agent
1076
 6.7 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Approved
8583
VIZAMYL

Approved Use

Vizamyl is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) or other causes of cognitive decline.

Launch Date

2013
Doses

Doses

DosePopulationAdverse events​
185 MBq 1 times / day single, intravenous
Recommended
Dose: 185 MBq, 1 times / day
Route: intravenous
Route: single
Dose: 185 MBq, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
unknown, 62 (18-93)
Health Status: unknown
Age Group: 62 (18-93)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
Other AEs: Hypersensitivity reaction...
Other AEs:
Hypersensitivity reaction (grade 3-4, 1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
355.9 MBq 1 times / day single, intravenous
Recommended
Dose: 355.9 MBq, 1 times / day
Route: intravenous
Route: single
Dose: 355.9 MBq, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf
unhealthy, 72
Health Status: unhealthy
Age Group: 72
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf
Disc. AE: Anaemia...
AEs leading to
discontinuation/dose reduction:
Anaemia
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf
AEs

AEs

AESignificanceDosePopulation
Hypersensitivity reaction grade 3-4, 1%
185 MBq 1 times / day single, intravenous
Recommended
Dose: 185 MBq, 1 times / day
Route: intravenous
Route: single
Dose: 185 MBq, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
unknown, 62 (18-93)
Health Status: unknown
Age Group: 62 (18-93)
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203137s013lbl.pdf
Anaemia Disc. AE
355.9 MBq 1 times / day single, intravenous
Recommended
Dose: 355.9 MBq, 1 times / day
Route: intravenous
Route: single
Dose: 355.9 MBq, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf
unhealthy, 72
Health Status: unhealthy
Age Group: 72
Sex: F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203137Orig1s000MedR.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP
303
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP
303
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
PubMed

PubMed

TitleDatePubMed
Alzheimer's imaging agents struggle to find a market outside trials.
2013-12
Multidentate (18)F-polypegylated styrylpyridines as imaging agents for Aβ plaques in cerebral amyloid angiopathy (CAA).
2011-12-08
Clinical amyloid imaging in Alzheimer's disease.
2011-07
Patents

Patents

20080219931
2

Sample Use Guides

In Vivo Use Guide
The recommended dose for Vizamyl is 185 megabecquerels (MBq) [5 millicuries (mCi)] in a maximum dose volume of 10 mL, administered as a single intravenous bolus within 40 seconds. The maximum mass dose is 20 micrograms. Follow the injection with an intravenous flush of 5 to 15 mL of 0.9% sterile sodium chloride injection.
Route of Administration: Intravenous
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:21:27 GMT 2025
Edited
by admin
on Mon Mar 31 18:21:27 GMT 2025
Record UNII
L49M066S0O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FLUTEMETAMOL (18F)
INN   WHO-DD  
INN  
Preferred Name English
FLUTEMETAMOL F-18
DASH  
Common Name English
FLUTEMETAMOL ((SUP18)F)
Common Name English
(18F)FLUTEMETAMOL [MI]
Common Name English
VIZAMYL
Brand Name English
flutemetamol (¹?F) [INN]
Common Name English
2-(3-(SUP 18)F)FLUORO-4-(METHYLAMINO)PHENYL)-1,3-BENZOTHIAZOL-6-OL
Common Name English
(18F)AH110690
Code English
FLUTEMETAMOL F-18 [ORANGE BOOK]
Common Name English
FLUTEMETAMOL F 18 [USAN]
Common Name English
FLUTEMETAMOL F 18
USAN  
USAN  
Official Name English
Flutemetamol (18f) [WHO-DD]
Common Name English
AH-110690 F-18
Code English
Classification Tree Code System Code
NDF-RT N0000177914
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
WHO-VATC QV09AX04
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
EMA ASSESSMENT REPORTS VIZAMYL (AUTHORIZED: ALZHEIMER DISEASE)
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
NCI_THESAURUS C2124
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
WHO-ATC V09AX04
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
EMA ASSESSMENT REPORTS VIZAMYL (AUTHORIZED: RADIONUCLIDE IMAGING)
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
Code System Code Type Description
PUBCHEM
15950376
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
SMS_ID
100000127579
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
INN
9169
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
ChEMBL
CHEMBL579205
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
RXCUI
1486025
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY RxNorm
DAILYMED
L49M066S0O
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
WIKIPEDIA
Flutemetamol (18F)
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
CAS
765922-62-1
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
LACTMED
Flutemetamol F 18
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
DRUG BANK
DB09151
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
DRUG CENTRAL
4301
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
CHEBI
76611
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
FDA UNII
L49M066S0O
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
MERCK INDEX
m11676
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
EPA CompTox
DTXSID80227394
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
EVMPD
SUB33652
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
NCI_THESAURUS
C90938
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
USAN
ZZ-74
Created by admin on Mon Mar 31 18:21:27 GMT 2025 , Edited by admin on Mon Mar 31 18:21:27 GMT 2025
PRIMARY
Related Record Type Details
Structure of FLUTEMETAMOL
NON-LABELED -> LABELED
Related Record Type Details
Structure of N-nitroso-flutemetamol f-18
IMPURITY -> PARENT
Related Record Type Details
Structure of FLUTEMETAMOL F-18
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966